Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

LipoScience Facing A Long, Hard Slog

(Editors' Note: This article covers a stock that is trading at less than $1 per share and/or has less than a $100 million market cap. Please be aware of the risks associated with these stocks.)

Writing anything positive about LipoScience (NASDAQ:LPDX) was a losing move in 2013, as the stock moved steadily down throughout the year. Making matters worse, it wasn't just a "the market doesn't get it" phenomenon as the company logged three straight quarters with revenue year-on-year revenue declines - something nobody wants to see from a company that is supposed to be in the early days of a major product launch.

I continue to believe there's still hope here, even if that hope has been...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
  • Access Top Ideas, chosen by Seeking Alpha’s editors
  • Filter long and short ideas by market cap and sector
  • Get Coverage of over 5,000 stocks, many of which have little or no coverage elsewhere
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO." Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else." Patrick Rice, Mainstay Capital Management
100% Satisfaction Guaranteed
Money back guarantee. Seeking Alpha PRO members receive a no-questions-asked refund for membership on months paid and not used. Details